Christian D Sadik

List of Publications by Year
in descending order

86	3,013	236833	175177
papers	citations	25 h-index	52 g-index

90	90	90	4597
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Neutrophils cascading their way to inflammation. Trends in Immunology, 2011, 32, 452-460.	2.9	461
2	Lipid-Cytokine-Chemokine Cascade Drives Neutrophil Recruitment in a Murine Model of Inflammatory Arthritis. Immunity, 2010, 33, 266-278.	6.6	301
3	Inhibition of 15-lipoxygenases by flavonoids: structureâ€“activity relations and mode of action. Biochemical Pharmacology, 2003, 65, 773-781.	2.0	281
4	Lipid-cytokine-chemokine cascades orchestrate leukocyte recruitment in inflammation. Journal of Leukocyte Biology, 2011, 91, 207-215.	1.5	191
5	Neutrophils orchestrate their own recruitment in murine arthritis through C5aR and FcÎ³R signaling. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, E3177-85.	3.3	120
6	Polyphenols of Cocoa: Inhibition of Mammalian 15-Lipoxygenase. Biological Chemistry, 2001, 382, 1687-96.	1.2	115
7	Epidermolysis Bullosa Acquisita: From Pathophysiology to Novel Therapeutic Options. Journal of Investigative Dermatology, 2016, 136, 24-33.	0.3	94
8	IL-17A is functionally relevant and a potential therapeutic target in bullous pemphigoid. Journal of Autoimmunity, 2019, 96, 104-112.	3.0	85
9	Epicatechin Selectively Prevents Nitration but Not Oxidation Reactions of Peroxynitrite. Biochemical and Biophysical Research Communications, 2001, 285, 782-787.	1.0	83
10	The critical role of C5a as an initiator of neutrophil-mediated autoimmune inflammation of the joint and skin. Seminars in Immunology, 2018, 37, 21-29.	2.7	79
11	The Leukotriene B4 and its Receptor BLT1ÂActÂas Critical Drivers of Neutrophil Recruitment in Murine Bullous Pemphigoid-Like Epidermolysis Bullosa Acquisita. Journal of Investigative Dermatology, 2017, 137, 1104-1113.	0.3	73
12	BP180-specific IgG is associated with skin adverse events, therapy response, and overall survival in non-small cell lung cancer patients treated with checkpoint inhibitors. Journal of the American Academy of Dermatology, 2020, 82, 854-861.	0.6	64
13	Gene Expression Analysis Reveals Novel Shared Gene Signatures and Candidate Molecular Mechanisms between Pemphigus and Systemic Lupus Erythematosus in CD4+ T Cells. Frontiers in Immunology, 2017, 8, 1992.	2.2	56
14	Pemphigoid gestationis: Toward a better understanding of the etiopathogenesis. Clinics in Dermatology, 2016, 34, 378-382.	0.8	50
15	Severe bullous pemphigoid associated with pembrolizumab therapy for metastatic melanoma with complete regression. Clinical and Experimental Dermatology, 2017, 42, 309-312.	0.6	49
16	Dual inhibition of complement factor 5 and leukotriene B4 synergistically suppresses murine pemphigoid disease. JCI Insight, 2019, 4, .	2.3	43
17	IL-17RA Signaling Amplifies Antibody-Induced Arthritis. PLoS ONE, 2011, 6, e26342.	1.1	37
18	INTERLEUKIN-22 DETECTED IN PATIENTS WITH ABDOMINAL SEPSIS. Shock, 2010, 34, 337-340.	1.0	36

#	Article	IF	Citations
19	Gene-diet interactions associated with complex trait variation in an advanced intercross outbred mouse line. Nature Communications, 2019, 10, 4097.	5.8	35
20	Meeting Report of the Pathogenesis of Pemphigus and Pemphigoid Meeting in Munich, September 2016. Journal of Investigative Dermatology, 2017, 137, 1199-1203.	0.3	34
21	Incidence of pemphigoid diseases in Northern Germany in 2016 â€“ first data from the SchleswigâEHolstein Registry of Autoimmune Bullous Diseases. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 1197-1202.	1.3	34
22	Dexamethasone suppresses interleukin-22 associated with bacterial infection in vitro and in vivo. Clinical and Experimental Immunology, 2009, 157, 370-376.	1.1	33
23	Resolution in bullous pemphigoid. Seminars in Immunopathology, 2019, 41, 645-654.	2.8	29
24	Perspective From the 5th International Pemphigus and Pemphigoid Foundation Scientific Conference. Frontiers in Medicine, 2018, 5, 306.	1.2	27
25	Activation of interferon regulatory factor-3 via toll-like receptor 3 and immunomodulatory functions detected in A549 lung epithelial cells exposed to misplaced U1-snRNA. Nucleic Acids Research, 2009, 37, 5041-5056.	6.5	26
26	Checkpoint Inhibition May Trigger the Rare Variant of Anti-LAD-1 IgG-Positive, Anti-BP180 NC16A IgG-Negative Bullous Pemphigoid. Frontiers in Immunology, 2019, 10, 1934.	2.2	26
27	Sevoflurane and isoflurane decrease TNF-Î±-induced gene expression in human monocytic THP-1 cells: Potential role of intracellular IÎºBÎ± regulation. International Journal of Molecular Medicine, 2009, 23, 665-71.	1.8	25
28	Leukotrienes orchestrating allergic skin inflammation. Experimental Dermatology, 2013, 22, 705-709.	1.4	25
29	Retrospective Analysis of Checkpoint Inhibitor Therapy-Associated Cases of Bullous Pemphigoid From Six German Dermatology Centers. Frontiers in Immunology, 2020, 11, 588582.	2.2	24
30	Oral administration of the selective <scp>GPR</scp>120/<scp>FFA</scp>4 agonist compound A is not effective in alleviating tissue inflammation in mouse models of prototypical autoimmune diseases. Pharmacology Research and Perspectives, 2018, 6, e00438.	1.1	20
31	Macrophage Migration Inhibitory Factor (MIF) Drives Murine Psoriasiform Dermatitis. Frontiers in Immunology, 2018, 9, 2262.	2.2	20
32	The Immunometabolomic Interface Receptor Hydroxycarboxylic Acid Receptor 2 Mediates the Therapeutic Effects of Dimethyl Fumarate in Autoantibody-Induced Skin Inflammation. Frontiers in Immunology, 2018, 9, 1890.	2.2	19
33	Evaluation of Nomacopan for Treatment of Bullous Pemphigoid. JAMA Dermatology, 2022, 158, 641.	2.0	19
34	The genetic difference between C57Bl/6J and C57Bl/6N mice significantly impacts Aldaraâ„¢â€induced psoriasiform dermatitis. Experimental Dermatology, 2017, 26, 349-351.	1.4	18
35	Uncoupling protein 2 protects mice from aging. Mitochondrion, 2016, 30, 42-50.	1.6	17
36	GPR15 is not critically involved in the regulation of murine psoriasiform dermatitis. Journal of Dermatological Science, 2019, 94, 196-204.	1.0	17

#	Article	IF	Citations
37	A Mitochondrial Polymorphism Alters Immune Cell Metabolism and Protects Mice from Skin Inflammation. International Journal of Molecular Sciences, 2021, 22, 1006.	1.8	17
38	IFN-gamma Impairs Release of IL-8 by IL-1beta-stimulated A549 Lung Carcinoma Cells. BMC Cancer, 2008, 8, 265.	1.1	16
39	Genomewide association study identifies GALC as susceptibility gene for mucous membrane pemphigoid. Experimental Dermatology, 2017, 26, 1214-1220.	1.4	16
40	Identification of two novel bullous pemphigoid- associated alleles, HLA-DQA1*05:05 and -DRB1*07:01, in Germans. Orphanet Journal of Rare Diseases, 2021, 16, 228.	1.2	16
41	Dapsone Suppresses Disease in Preclinical Murine Models of Pemphigoid Diseases. Journal of Investigative Dermatology, 2021, 141, 2587-2595.e2.	0.3	16
42	The Sphingosine-1-Phosphate Receptor Modulator Fingolimod Aggravates Murine Epidermolysis BullosaÂAcquisita. Journal of Investigative Dermatology, 2019, 139, 2381-2384.e3.	0.3	15
43	Recent progresses and perspectives in autoimmune bullous diseases. Journal of Allergy and Clinical Immunology, 2020, 145, 1145-1147.	1.5	15
44	Value of BIOCHIP Technology in the Serological Diagnosis of Pemphigoid Gestationis. Acta Dermato-Venereologica, 2017, 97, 128-130.	0.6	14
45	Systematic analysis highlights the key role of TLR2/NF-ÎºB/MAP kinase signaling for IL-8 induction by macrophage-like THP-1 cells under influence of Borrelia burgdorferi lysates. International Journal of Biochemistry and Cell Biology, 2008, 40, 2508-2521.	1.2	13
46	Sphingosineâ€1â€phosphate modulators in inflammatory skin diseases â€“ lining up for clinical translation. Experimental Dermatology, 2017, 26, 206-210.	1.4	13
47	The G Protein-Coupled Receptor (GPR) 15 Counteracts Antibody-Mediated Skin Inflammation. Frontiers in Immunology, 2020, 11, 1858.	2.2	13
48	Coexistence of bullous pemphigoid with neuropsychiatric comorbidities is associated with antiâ€BP230 seropositivity. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 2067-2073.	1.3	13
49	Evaluation and Comparison of Clinical and iLaboratory Characteristics of Patients With IgA Epidermolysis Bullosa Acquisita, Linear IgA Bullous Dermatosis, and IgG Epidermolysis Bullosa Acquisita. JAMA Dermatology, 2021, 157, 917.	2.0	12
50	Leukotrienes Do Not Modulate the Course of Aldaraâ„¢-induced Psoriasiform Dermatitis in Mice. Acta Dermato-Venereologica, 2015, 95, 341-342.	0.6	11
51	GM-CSF in murine psoriasiform dermatitis: Redundant and pathogenic roles uncovered by antibody-induced neutralization and genetic deficiency. PLoS ONE, 2017, 12, e0182646.	1.1	11
52	Expression of PDâ€1 and Timâ€3 is increased in skin of patients with bullous pemphigoid and pemphigus vulgaris. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 486-492.	1.3	10
53	Current treatments and developments in pemphigoid diseases as paradigm diseases for autoantibody-driven, organ-specific autoimmune diseases. Seminars in Hematology, 2016, 53, S51-S53.	1.8	9
54	First emergence of pyoderma gangraenosum, palmoplantar pustulosis and sacroiliitis in a psoriasis patient associated with switching from secukinumab to brodalumab. Journal of the European Academy of Dermatology and Venereology, 2019, 33, e406-e407.	1.3	9

#	Article	IF	Citations
55	FcÎ³ Receptor IIB Controls Skin Inflammation in an Active Model of Epidermolysis Bullosa Acquisita. Frontiers in Immunology, 2019, 10, 3012.	2.2	9
56	Characterization of the skin microbiota in bullous pemphigoid patients and controls reveals novel microbial indicators of disease. Journal of Advanced Research, 2023, 44, 71-79.	4.4	9
57	Automated direct immunofluorescence analyses of skin biopsies. Journal of Cutaneous Pathology, 2016, 43, 227-235.	0.7	8
58	Dissecting genetics of cutaneous miRNA in a mouse model of an autoimmune blistering disease. BMC Genomics, 2016, 17, 112.	1.2	8
59	Primary Cutaneous Gamma-Delta T-Cell Lymphoma With Long-Term Indolent Clinical Course Initially Mimicking Lupus Erythematosus Profundus. Frontiers in Oncology, 2020, 10, 133.	1.3	7
60	MicroRNAs in pemphigus and pemphigoid diseases. Autoimmunity Reviews, 2021, 20, 102852.	2.5	7
61	C5aR2 Deficiency Ameliorates Inflammation inÂMurine Epidermolysis Bullosa Acquisita by Regulating FcÎ³ Receptor Expression on Neutrophils. Journal of Investigative Dermatology, 2022, 142, 2715-2723.e2.	0.3	7
62	Cytokine production by leukocytes of Papillonâ€“LefÃ¨vre syndrome patients in whole blood cultures. Clinical Oral Investigations, 2012, 16, 591-597.	1.4	6
63	Skin-Specific Drug Delivery: A Rapid Solution to Skin Diseases?. Journal of Investigative Dermatology, 2013, 133, 2135-2137.	0.3	6
64	12/15-Lipoxygenase choreographs the resolution of IgG-mediated skin inflammation. Journal of Autoimmunity, 2020, 115, 102528.	3.0	5
65	Immunomodulator Galectin-9 is Increased in Blood and Skin of Patients with Bullous Pemphigoid. Acta Dermato-Venereologica, 2021, 101, adv00419.	0.6	5
66	Polymorphisms in the Mitochondrial Genome Are Associated With Bullous Pemphigoid in Germans. Frontiers in Immunology, 2019, 10, 2200.	2.2	4
67	Immunoglobulin G of systemic sclerosis patients programs a pro-inflammatory and profibrotic phenotype in monocyte-like THP-1 cells. Rheumatology, 2020, 60, 3012-3022.	0.9	4
68	The G proteinâ€coupled receptor 15 (GPR15) regulates cutaneous immunology by maintaining dendritic epidermal T cells and regulating the skin microbiome. European Journal of Immunology, 2021, 51, 1390-1398.	1.6	4
69	Serum autoantibody reactivity in bullous pemphigoid is associated with neuropsychiatric disorders and the use of antidiabetics and antipsychotics: a large, prospective cohort study. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 2181-2189.	1.3	4
70	Optimization of reference gene panels for gene expression analysis in preclinical models of inflammatory skin diseases. Experimental Dermatology, 2019, 28, 985-988.	1.4	3
71	Inhibition of Glucose Metabolism Abrogates the Effector Phase of Bullous Pemphigoid-Like Epidermolysis Bullosa Acquisita. Journal of Investigative Dermatology, 2021, 141, 1646-1655.e3.	0.3	3
72	BullÃ¶se Autoimmundermatosen. , 2018, , 839-873.		3

#	Article	IF	Citations
73	Mast cellâ€deficient mice Mcpt5Cre/Dicer ^{fl/fl} redefine the role of mast cells in experimental bullous pemphigoid. Skin Health and Disease, 2022, 2, .	0.7	3
74	47 Interleukin-22 in sepsis. Cytokine, 2008, 43, 247-248.	1.4	1
75	Neonatal Autoimmune Subepidermal IgG/IgA Blistering Disease With Severe Laryngeal and Esophageal Involvement: A Report of a Case and Review of the Literature. American Journal of Dermatopathology, 2020, 42, 783-786.	0.3	1
76	Editorial: Skin Autoimmunity. Frontiers in Immunology, 2021, 12, 627565.	2.2	1
77	Interleukin 17. , 2014, , 1-8.		0
78	253 12/15-lipoxygenase aggravates psoriasiform dermatitis. Journal of Investigative Dermatology, 2016, 136, S204.	0.3	0
79	258 Macrophage Migration Inhibitory Factor (MIF) promotes T H 17 cell-driven psoriasiform dermatitis. Journal of Investigative Dermatology, 2016, 136, S205.	0.3	0
80	SAT0320â€…SSC- IGG effects are mediated through distinct pathways in THP-1 cells. , 2017, , .		0
81	Ein ungewÃ¶hnlicher Fall von Lichen ruber planus mit vorausgegangenem bullÃ¶sem Pemphigoid bei einem 20â€jÃhrigen Patienten. JDDG - Journal of the German Society of Dermatology, 2019, 17, 7-8.	0.4	0
82	049 Dual inhibition of the complement factor C5 and leukotriene B4by the bifunctional soft tick-derived lipocalin Coversin synergizes in suppressing disease in a murine model of bullous pemphigoid-like epidermolysis bullosa acquisita. Journal of Investigative Dermatology, 2019, 139, S9.	0.3	0
83	Autoimmune Bullous Diseases. , 2021, , 1-34.		0
84	Interleukin 17. , 2016, , 717-723.		0
85	BullÃ¶se Autoimmundermatosen. , 2017, , 1-36.		0
86	Autoimmune Bullous Diseases. , 2020, , 1-34.		0